Orthocell Deepens Stake in Marine Biomedical and Secures Rights to PearlBone Bone Regeneration Technology

An announcement from Orthocell Ltd ( (AU:OCC) ) is now available.

Orthocell has executed a binding agreement with Marine Biomedical Pty Ltd, lifting its equity stake from 1.72% to 11.7% for AU$1.05 million and securing a first right of refusal over global distribution rights for PearlBone, a next-generation bone substitute made from sustainably sourced pearl shells, as well as future bone repair products. The deal converts a prior memorandum into a formal strategic partnership, broadening Orthocell’s offering into bone regeneration alongside its existing nerve and tendon repair technologies and positioning it as a multi-tissue regenerative medicine provider targeting complex trauma and reconstructive procedures. With Marine Biomedical progressing PearlBone toward a U.S. FDA 510(k) submission and potential entry into the US$1.6 billion global bone substitute market, Orthocell aims to capitalise on its U.S. distribution network, supported by robust cash reserves of $49.4 million to fund ongoing commercial expansion.

The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

More about Orthocell Ltd

Orthocell Ltd is an Australian regenerative medicine company focused on developing and commercialising biologically advanced therapies for nerve, tendon and now bone repair. Leveraging a portfolio of collagen-based and other biologic devices, the company targets orthopaedic, trauma and reconstructive surgery markets, particularly in the United States where it has established specialist distribution relationships and strong engagement with orthopaedic and plastic surgeons.

Average Trading Volume: 666,907

Technical Sentiment Signal: Buy

Current Market Cap: A$276.7M

See more data about OCC stock on TipRanks’ Stock Analysis page.